Promotion Pact Broadens Conceptus’ Market For Birth-Control Device
This article was originally published in The Gray Sheet
Executive Summary
Conceptus is redoubling efforts to sell non-incisional birth control to physician offices after failing to acquire Ovion
You may also be interested in...
Bayer Buys Essure Contraceptive-Maker Conceptus For $1.1 Billion
The acquisition will add a popular nonsurgical, permanent birth control device to Bayer’s line of contraceptive pharmaceuticals and women’s health products.
AMS May Enter Permanent Birth-Control Market Via Merger Or License
Conceptus has less than three weeks to decide whether to purchase Ovion or to allow the transcervical sterilization device developer to merge with American Medical Systems
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”